Dehydroepiandrosterone
From DrugPedia: A Wikipedia for Drug discovery
(Difference between revisions)
| Line 101: | Line 101: | ||
|LD50 | |LD50 | ||
|subcutaneous | |subcutaneous | ||
| - | |900mg/kg (900mg/kg) | + | |900mg/kg (900mg/kg) |
| + | | | ||
|British UK Patent Application. Vol. #2208473, | |British UK Patent Application. Vol. #2208473, | ||
|- | |- | ||
| Line 107: | Line 108: | ||
|LD50 | |LD50 | ||
|oral | |oral | ||
| - | |> 10gm/kg (10000mg/kg) | + | |> 10gm/kg (10000mg/kg) |
| + | | | ||
|British UK Patent Application. Vol. #2208473, | |British UK Patent Application. Vol. #2208473, | ||
|- | |- | ||
| Line 113: | Line 115: | ||
|LD50 | |LD50 | ||
|subcutaneous | |subcutaneous | ||
| - | |1gm/kg (1000mg/kg) | + | |1gm/kg (1000mg/kg) |
| + | | | ||
|British UK Patent Ap | |British UK Patent Ap | ||
|- | |- | ||
|} | |} | ||
Revision as of 05:29, 31 October 2008
Dehydroepiandrosterone
Pubchem(5881)
A major C19 steroid produced by the ADRENAL CORTEX. It is also produced in small quantities in the TESTIS and the OVARY. Dehydroepiandrosterone (DHEA) can be converted to TESTOSTERONE; ANDROSTENEDIONE; ESTRADIOL; and ESTRONE. Most of DHEA is sulfated (DEHYDROEPIANDROSTERONE SULFATE) before secretion.
Negative modulator of GABAA receptors.
Drug Type: Small Molecule; Experimental
KEGG Pathway(C01227) Androgen and estrogen metabolism Prostate cancer
| MMDB ID | PDB ID | Reference |
|---|---|---|
| 15983 | 1E3R | Ha NC, Kim MS, Lee W, Choi KY, Oh BHDetection of large pKa perturbations of an inhibitor and a catalytic group at an enzyme active site, a mechanistic basis for catalytic power of many enzymesJ. Biol. Chem. v275, p.41100-41106 |
| 55806 | 1COY | Li J, Vrielink A, Brick P, Blow DMCrystal structure of cholesterol oxidase complexed with a steroid substrate: implications for flavin adenine dinucleotide dependent alcohol oxidasesBiochemistry v32, p.11507-11515 |
| Physical Property | Value | Units | Temp (deg C) | Source |
|---|---|---|---|---|
| Melting Point | 140-141 | deg C | EXP | |
| log P (octanol-water) | 3.23 | (none) | EXP | |
| Water Solubility | 63.5 | mg/L | 25 | EXP |
| Vapor Pressure | 2.23E-08 | mm Hg | 25 | EST |
| Henry's Law Constant | 6.62E-09 | atm-m3/mole | 25 | EST |
| Atmospheric OH Rate Constant | 1.27E-10 | cm3/molecule-sec | 25 | EST |
| Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
|---|---|---|---|---|---|
| man | TDLo | oral | 10mg/kg/2W-I (10mg/kg) | CARDIAC: ARRHYTHMIAS (INCLUDING CHANGES IN CONDUCTION) | Annals of Internal Medicine. Vol. 129, Pg. 588, 1998. |
| mouse | LD50 | oral | > 10gm/kg (10000mg/kg) | British UK Patent Application. Vol. #2208473, | |
| mouse | LD50 | subcutaneous | 900mg/kg (900mg/kg) | British UK Patent Application. Vol. #2208473, | |
| rat | LD50 | oral | > 10gm/kg (10000mg/kg) | British UK Patent Application. Vol. #2208473, | |
| rat | LD50 | subcutaneous | 1gm/kg (1000mg/kg) | British UK Patent Ap |
